Presentation is loading. Please wait.

Presentation is loading. Please wait.

Public/Private Partnerships in Global Health Initiatives

Similar presentations

Presentation on theme: "Public/Private Partnerships in Global Health Initiatives"— Presentation transcript:

1 Public/Private Partnerships in Global Health Initiatives
Gerald J. Siuta, Ph.D., CLP Consultant, Business Development New York University Global Health Alliance New York City, NY March 27, 2009

2 Global Tuberculosis Epidemic
One-third of the world’s population is infected with Mycobacterium tuberculosis (M.tb.) 2 billion people 8-9 million develop active disease annually 2 million deaths occur each year 1 person dies every 15 seconds 400,000 cases of MDR-TB each year Leading cause of death in HIV-positive people 12 Million people are TB/HIV co-infected TB’s economic toll: $16 billion a year

3 Current TB Drug Therapy
Active TB Standard therapy – 4 drugs (isoniazid, rifampin, pyrazinamide & ethambutol) for 2 months, followed by isoniazid and rifampin for 4 months Latent TB Standard therapy – isoniazid for 9 months Multi-Drug Resistant TB (MDR-TB) Individualized, prolonged therapy, few available drugs, poorly tolerated and difficult to administer TB/HIV Co-Infection Treatment as in active TB, but drug interactions with antiretroviral agents make simultaneous therapy difficult Extensively Drug Resistant TB (XDR-TB) No treatment available

4 The Need for New TB Drugs
Complex 6-9 months treatment with a drug combination regimen No new anti-TB drug in over 40 years TB/HIV co-infections fueling each other MDR-TB is on the rise Unattractive market for private sector No capitalization of public sector research

5 History of the TB Alliance
Cape Town Declaration – February 2000 Hosts: Rockefeller Foundation and the Medical Research Council of South Africa Over 120 organizations (health, science, philanthropy and private industry) Results Support goals of Stop TB Initiative Create Scientific Blueprint Develop Pharmacoeconomic Analysis Build a Global Alliance for TB Drug Development

6 The TB Alliance Independent, international Product Development Partnership founded in October 2000 Non-profit organization Headquarters in New York City Offices in Brussels and Cape Town Entrepreneurial, virtual R&D approach Out-source R&D to public and private partners Pro-active fundraising Over US $200 million raised Support ~ 200 FTE worldwide and 38 FTE in-house

7 Our Mission Develop an entirely new therapeutic regimen that will shorten or simplify the treatment of tuberculosis Coordinate and act as catalyst for global TB drug development activities Ensure Affordability, Adoption and Access (AAA Strategy)

8 AAA Strategy Affordability Adoption Access
Appropriate pricing in developing countries Adoption Ensure that new drugs are incorporated into existing treatment programs Access Procurement and distribution to those patients who need them most

9 Our Vision FDCs 10 Days 2 Months 6 Months

10 Profile of a New TB Drug Shorten treatment to less than 2 months
Novel mechanism of action (MDR/XDR-TB) Orally active Once daily or intermittent therapy Compatible with HIV treatment Low cost of goods

11 Financial Support Bill and Melinda Gates Foundation
Rockefeller Foundation Netherlands Ministry for Development Cooperation United States Agency for International Development (USAID) Governments of Great Britain and Ireland

12 Types of Deals In-Licensing IP Assignment Sponsored R&D
Collaborative R&D Freedom to Operate Clinical Trials

13 Industrial Partners Bayer HealthCare Chiron/Novartis GlaxoSmithKline
Novartis Institute for Tropical Diseases sanofi-aventis

14 Academic Partners Infectious Disease Research Institute
Institute of Materia Medica (China) Johns Hopkins University Korea Research Institute of Chemical Technology/Yonsei University (South Korea) Rutgers, The State University of New Jersey Texas A&M University University of Auckland (New Zealand) University of Illinois at Chicago University of Pennsylvania

CLINICAL DEVELOPMENT Lead Identification Lead Optimization Preclinical Phase I Phase II Phase III Moxifloxacin PA-824 Quinolone TBK-613 Nitroimidazoles Pleuromutilins Mycobacterial Gyrase Inhibitors Multifunctional Molecules InhA Inhibitors Riminophenazines Phenotypic Screening Focused Screening Malate Synthase Inhibitors Protease Inhibitors Energy Metabolism Inhibitors RNA Polymerase Inhibitors NITD Portfolio 15

16 Bayer HealthCare Moxifloxacin Fluoroquinolone antibiotic Orally active
Once-a-day dosage Approved in 104 countries for the treatment of bacterial respiratory and skin infections

17 Bayer HealthCare Moxifloxacin Fluoroquinolone antibiotic Orally active
Once-a-day dosage Approved in 104 countries for the treatment of bacterial respiratory and skin infections

18 Moxifloxacin for TB Novel mechanism of action: kills M.tb. by inhibition of DNA gyrase In vivo studies showed moxifloxacin reduced treatment time by two months when substituted for isoniazid Safe to use with antiretroviral agents since it is not metabolized by the cytochrome P-450 enzyme system

19 The Partnership Clinically assess the efficacy and safety of moxifloxacin as a front-line agent for the treatment of TB If clinical trials are successful, register moxifloxacin for a TB indication Committed to making the product affordable and accessible to patients in the developing world

20 Moxifloxacin Clinical Trials
Evaluate whether substitution of moxifloxacin for one of the standard TB drugs (isoniazid or ethambutol) eliminates TB infection faster than current therapy Trials to be run in Brazil, Canada, South Africa, Spain, Tanzania, Uganda, the United States and Zambia More than 3,000 TB patients to be enrolled

21 Bayer Commitments Donate moxifloxacin for each clinical trial site
Cover costs of regulatory filings Provide moxifloxacin at an affordable price for patients with TB in the developing world

22 TB Alliance Commitments
Coordinate and help cover the costs of the clinical trials Ensure coordination of information and results towards the goal of registration Leverage substantial support from: U.S. Centers for Disease Control and Prevention (CDC) Orphan Products Development Center of the U.S. Food & Drug Administration European and Developing Countries Clinical Trials Partnership (EDCTP)

23 Chiron/Novartis PA-824 – A novel nitroimidazole
Discovered by Pathogenesis, Inc. Distinct mechanism of action Potent activity against both active and slow growing M.tb. Possesses both bactericidal and sterilizing activity

24 Chiron/Novartis Worldwide exclusive license for the treatment of tuberculosis Defined scientific milestones Grant-back option Manufacturing rights No royalties in developing world

25 Korea Research Institute of Chemical Technology (KRICT)
Located in Daejeon, South Korea Synthesized more than 600 quinolones, pyridones & quinolizines In vitro and in vivo biological testing at the Yonsei University College of Medicine in Seoul, South Korea One lead compound has been selected for further preclinical evaluation

26 University of Auckland
Synthesis of PA-824 analogs Identified many new pharmacophores, several of which have demonstrated potent activity against TB Optimization has led to nitroimidazole analogs that have in vitro activity greater than PA-824

27 GlaxoSmithKline Joint drug discovery program at GSK’s Diseases of the Developing World facility in Tres Cantos, Spain Five individual projects: Mycobacterial gyrase inhibitors InhA inhibitors Malate synthase inhibitors Pleuromutilins Focused screening

28 Institute of Materia Medica
Joint research partnership for the design, synthesis and evaluation of a class of compounds known as riminophenazines Class was discovered in the 1950s The collaboration will utilize IMM's expertise and integrated capabilities in chemistry, pharmacology and manufacture

29 Global Alliance for TB Drug Development

Download ppt "Public/Private Partnerships in Global Health Initiatives"

Similar presentations

Ads by Google